Beijing Tide Pharmaceutical Becomes Biggest Shareholder Of Japanese LTT Bio-Pharma
This article was originally published in PharmAsia News
Executive SummaryAccording to a recent disclosure filed by LTT Bio-Pharma, a Japanese biotech startup focusing on drug delivery system discovery, Beijing Tide Pharmaceutical acquired 2,320 company shares previously owned by now-bankrupt Asklepios and became the largest shareholder with 25,320 shares. The shares account for 19.2 percent of LTT Bio-Pharma's outstanding shares. (Click here for more - Japanese language
You may also be interested in...
Lannett’s Phase I trial for biosimilar insulin glargine has met “all primary endpoints,” the company has announced. The rival to Sanofi’s Lantus is being developed by Lannett with partner HEC through a deal for which financial details have just been revealed.
Sanofi Consumer Healthcare is to operate as a standalone unit in a move which is being viewed as a prelude to a potential spin-off. High profile prescription-to-OTC switches are a priority for the revamped business.
Data integrity issues were raised in many warning letters to active pharmaceutical ingredient manufacturers over the past four years.